Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Alena I. Zagrebneva"'
Autor:
Ulyana A. Markina, Daria S. Fomina, Marina S. Lebedkina, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva, Zinaida Yu. Mutovina, Alexander V. Karaulov, Ekaterina I. Alexeeva, Mariana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 94, Iss 5, Pp 675-682 (2022)
Background. The use of virus-neutralizing monoclonal antibodies is an effective method of etiotropic therapy for SARS-CoV-2 in patients of high-risk groups of severe COVID-19. Regdanvimab is a single-component monoclonal antibodies immunoglobulin G1,
Externí odkaz:
https://doaj.org/article/1ca7266523cb42cb8962e01de2e8c208
Autor:
Alexey I. Khripun, Andrey V. Starshinin, Yulia O. Antipova, Mariana A. Lysenko, Yulia V. Urozhaeva, Olga F. Gavrilenko, Natalya A. Rusantsova, Andrei A. Tyazhelnikov, Elena Yu. Tikhonovskaya, Natalia V. Okolot, Maria V. Sokolova, Daria S. Fomina, Elena N. Simonova, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva
Publikováno v:
Терапевтический архив, Vol 94, Iss 5, Pp 668-674 (2022)
Aim. To study the effect of levilimab or baricitinib in combination with standard therapy (ST) on the incidence of severe viral pneumonia associated with a new coronavirus infection COVID-19. Materials and methods. A multicenter, open-label observ
Externí odkaz:
https://doaj.org/article/6e1e406685f6453fb14793c3ed915970
Autor:
Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1316-1324 (2021)
Aim. To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes. Materials and methods. The single-center, non-randomized prospective study
Externí odkaz:
https://doaj.org/article/6b1c4220c5664b0daa936e831f62deb9
Autor:
Elena A. Baryakh, Olga L. Kochneva, Elena N. Misyurina, Evgenia I. Zhelnova, Konstantin V. Yatskov, Alena I. Zagrebneva, Rushan R. Zyangirov, Inna V. Samsonova, Natalia G. Poteshkina, Mariana A. Lysenko, Irina V. Poddubnaya
Publikováno v:
Современная онкология, Vol 22, Iss 2, Pp 74-78 (2020)
Justification. Oncological diseases, along with diabetes, hypertension, cardiovascular and chronic obstructive pulmonary diseases, are associated with severe course and worst prognosis of the new coronavirus infection COVID-19. Due to the limited num
Externí odkaz:
https://doaj.org/article/50904b24199748a6bb5bbcb279ee0fe2
Autor:
Ekaterina A Bryushkova, Valeria D Skatova, Zinaida Y Mutovina, Alena I Zagrebneva, Daria S Fomina, Tatyana S Kruglova, Anna A Akopyan, Irina D Strazhesko, Sergey A Lukyanov, Olga N Tkacheva, Maryana A Lysenko, Dmitry M Chudakov
Publikováno v:
PLoS ONE, Vol 17, Iss 8, p e0273340 (2022)
ObjectiveThe aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive thera
Externí odkaz:
https://doaj.org/article/a44ae77ecd41419f8b076c6872330722
Autor:
Alena I. Zagrebneva, Elena N. Simonova, Тatiana V. Mezenova, Natalia B. Burmistrova, Yuliya A. Gavrikova, Vladislav V. Dolgov, Evgeniya O. Morozova, Zhaneta M. Kodzeva, Ksenia S. Sapogina, Anastasia A. Fomina
Publikováno v:
HERALD of North-Western State Medical University named after I.I. Mechnikov. 14:83-92
The growing demand for biological disease-modifying antirheumatic drugs (bDMARDs) and their high cost put a heavy burden on the healthcare budget, thereby limiting the availability of treatment for patients. The introduction of bDMARDs biosimilars in
Autor:
Vladimir P. Chulanov, Bulat A. Bakirov, Natalia N. Vezikova, Vladimir N. Gorodin, Marina V. Zhuravleva, Alena I. Zagrebneva, Igor G. Ivanov, Nikita V. Lomakin, Galina V. Lukina, Diana L. Moysova, Zinaida I. Mutovina
Publikováno v:
Terapevticheskii arkhiv. 94(8)
The Advisory Board chaired by the chief specialist in infectious diseases of the Ministry of Health of Russian Federation, Professor V.P. Chulanov was held on June 18, 2022 in Saint Petersburg. Aim. The main purpose of the Board was following discuss
Autor:
Irina P. Beloglazova, Elena A. Kovalevskaуa, Inna V. Samsonova, M. A. Lysenko, Anton A. Chernov, Sof'ya A. Serdotetckova, Elena N. Bobrikova, Zinaida Yu. Mutovina, Dar'ya S. Fomina, Nadija F. Frolova, N. G. Poteshkina, Tat'yana N. Markova, Dar'ya B. Krlykova, Alena I. Zagrebneva, Tat'yana S. Kruglova, Oksana V. Manchenko
Publikováno v:
Russian Pulmonology. 30:164-172
According to accumulated clinical data, one of the causes of severe damage to lung epithelial cells associated with SARS-CoV-2 (2019-nCoV) is an acute, timely underestimated "cytokine storm" (cytokine cascade, hypercytokinaemia) with characteristic s
Autor:
Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko
Publikováno v:
Терапевтический архив, Vol 93, Iss 11, Pp 1316-1324 (2021)
To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes.The single-center, non-randomized prospective study included 190 patients with comm